San Francisco startup Composition Therapeutics can be working on an oral, the moment-each day GLP-1 drug named GSBR-1290—the drug surpassed Wall Street’s anticipations in June any time a mid-phase review showed typical weight loss of close to six% and it options to start out A furthe